<DOC>
	<DOCNO>NCT02157948</DOCNO>
	<brief_summary>This study compare effect denosumab produce two different manufacturing process bone mineral density lumbar spine postmenopausal woman osteoporosis .</brief_summary>
	<brief_title>A Double-blind Study Assess Efficacy Safety Denosumab Produced Two Different Processes Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Subject provide informed consent prior studyspecific activities/procedures Ambulatory postmenopausal woman . Age 55 year old Screening BMD value equivalent Tscore le equal 2.5 lumbar spine , total hip , femoral neck . Administration osteoporosis treatment bone active treatment within specific timeframes Vitamin D deficiency Diseases condition affect bone metabolism ( e.g. , hypo/hyperparathyroidism ; hypo/hyperthyroidism , unless stable wellcontrolled ) Contraindications denosumab therapy ( e.g. , hypocalcemia )</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>postmenopausal osteoporosis</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>denosumab</keyword>
	<keyword>woman</keyword>
</DOC>